0001193125-11-300941.txt : 20111108 0001193125-11-300941.hdr.sgml : 20111108 20111108073323 ACCESSION NUMBER: 0001193125-11-300941 CONFORMED SUBMISSION TYPE: FWP PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20111108 GROUP MEMBERS: TEVA PHARMACEUTICAL CO B.V. GROUP MEMBERS: TEVA PHARMACEUTICAL FINANCE IV, LLC GROUP MEMBERS: TEVA PHARMACEUTICAL INDUSTRIES LTD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL FINANCE IV B.V. CENTRAL INDEX KEY: 0001527029 IRS NUMBER: 000000000 STATE OF INCORPORATION: P8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: FWP SEC ACT: 1934 Act SEC FILE NUMBER: 333-155927-06 FILM NUMBER: 111186239 BUSINESS ADDRESS: STREET 1: SCHOTTEGATWEG OOST 29D CITY: CURACAO STATE: P8 ZIP: 00000 BUSINESS PHONE: 5999-736-6066 MAIL ADDRESS: STREET 1: SCHOTTEGATWEG OOST 29D CITY: CURACAO STATE: P8 ZIP: 00000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL FINANCE IV B.V. CENTRAL INDEX KEY: 0001527029 IRS NUMBER: 000000000 STATE OF INCORPORATION: P8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: FWP BUSINESS ADDRESS: STREET 1: SCHOTTEGATWEG OOST 29D CITY: CURACAO STATE: P8 ZIP: 00000 BUSINESS PHONE: 5999-736-6066 MAIL ADDRESS: STREET 1: SCHOTTEGATWEG OOST 29D CITY: CURACAO STATE: P8 ZIP: 00000 FWP 1 d253424dfwp.htm FREE WRITING PROSPECTUS Free Writing Prospectus

Filed Pursuant to Rule 433

Registration No. 333-155927

333-155927-08

333-155927-01

333-155927-06

November 7, 2011

FREE WRITING PROSPECTUS DATED NOVEMBER 7, 2011

(To the Prospectus dated December 4, 2008, as supplemented by

the Supplement dated August 25, 2011 and the Prospectus Supplement dated November 7, 2011, referred to

collectively as the “Preliminary Prospectus”)

 

LOGO    Teva Pharmaceutical Finance Company B.V.    LOGO
   $1,100,000,000 Floating Rate Senior Notes due 2013   
   $950,000,000 2.400% Senior Notes due 2016   
   $875,000,000 3.650% Senior Notes due 2021   
   Teva Pharmaceutical Finance IV, LLC   
   $200,000,000 Floating Rate Senior Notes due 2013   
   $1,000,000,000 1.700% Senior Notes due 2014   
   Teva Pharmaceutical Finance IV B.V.   
   $875,000,000 3.650% Senior Notes due 2021   
   Payment of principal and interest unconditionally guaranteed by   
   Teva Pharmaceutical Industries Limited   

 

Issuers:   

Teva Pharmaceutical Finance Company B.V. (“Teva BV”) will issue the Floating Rate Senior Notes due 2013 (the “Teva BV Floating Rate Notes”), the 2.400% Senior Notes due 2016 (the “2016 Notes”) and the 3.650% Senior Notes due 2021 (the “Teva BV 2021 Notes”)

 

Teva Pharmaceutical Finance IV, LLC (“Teva LLC”) will issue the Floating Rate Senior Notes due 2013 (the “Teva LLC Floating Rate Notes” and, together with the Teva BV Floating Rate Notes, the “Floating Rate Notes”) and the 1.700% Senior Notes due 2014 (the “2014 Notes”)

 

Teva Pharmaceutical Finance IV B.V. (“Teva IV BV”) will issue the 3.650% Senior Notes due 2021 (the “Teva IV BV 2021 Notes” and, together with the 2014 Notes, the 2016 Notes and the Teva BV 2021 Notes, the “Fixed Rate Notes”)

Guarantor:    Teva Pharmaceutical Industries Limited (“Teva”)
Ratings:   

A3 Stable / A- Stable

 

Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at anytime.

Trade Date:    November 7, 2011
Settlement Date (T+3):    November 10, 2011
Principal Amount:   

$1,100,000,000 for the Teva BV Floating Rate Notes

$200,000,000 for the Teva LLC Floating Rate Notes

$1,000,000,000 for the 2014 Notes

  

$950,000,000 for the 2016 Notes

$875,000,000 for the Teva BV 2021 Notes

$875,000,000 for the Teva IV BV 2021 Notes

Maturity:   

November 8, 2013 for the Teva BV Floating Rate Notes

May 8, 2013 for the Teva LLC Floating Rate Notes

November 10, 2014 for the 2014 Notes

November 10, 2016 for the 2016 Notes

November 10, 2021 for the Teva BV 2021 Notes

November 10, 2021 for the Teva IV BV 2021 Notes

Interest Rate:   

A rate equal to three-month LIBOR plus 0.900% for the Teva BV Floating Rate Notes and a rate equal to three-month LIBOR plus 0.800% for the Teva LLC Floating Rate Notes (each calculated as set forth under “Description of the Notes and the Guarantees–Payment of Interest and Principal–Interest on the Floating Rate Notes” in the Preliminary Prospectus)

1.700% for the 2014 Notes

2.400% for the 2016 Notes

3.650% for the Teva BV 2021 Notes

3.650% for the Teva IV BV 2021 Notes

Interest Payment Dates:   

February 8, May 8, August 8 and November 8 of each year, beginning February 8, 2012, and at maturity, with respect to the Floating Rate Notes of each series

 

May 10 and November 10 of each year, beginning May 10, 2012, and at maturity, with respect to the Fixed Rate Notes of each series

Underwriting Discount:   

0.150% ($1,650,000 total) for the Teva BV Floating Rate Notes

0.200% ($400,000 total) for the Teva LLC Floating Rate Notes

0.250% ($2,500,000 total) for the 2014 Notes

0.350% ($3,325,000 total) for the 2016 Notes

0.450% ($3,937,500 total) for the Teva BV 2021 Notes

0.450% ($3,937,500 total) for the Teva IV BV 2021 Notes

Public Offering Price:   

100.000% of principal amount for the Teva BV Floating Rate Notes

100.000% of principal amount for the Teva LLC Floating Rate Notes

99.869% of principal amount for the 2014 Notes

99.916% of principal amount for the 2016 Notes

99.635% of principal amount for the Teva BV 2021 Notes

99.635% of principal amount for the Teva IV BV 2021 Notes

 

in each case, plus accrued interest from November 10, 2011, if settlement occurs after that date

Yield to Maturity:   

1.745% for the 2014 Notes

2.418% for the 2016 Notes

3.694% for the Teva BV 2021 Notes

3.694% for the Teva IV BV 2021 Notes

Spread to Benchmark Treasury:   

+ 135 basis points for the 2014 Notes

+ 150 basis points for the 2016 Notes

+ 170 basis points for the Teva BV 2021 Notes

+ 170 basis points for the Teva IV BV 2021 Notes

Benchmark Treasury:   

0.500% due October 15, 2014 for the 2014 Notes

1.000% due October 31, 2016 for the 2016 Notes

2.125% due August 15, 2021 for the Teva BV 2021 Notes

2.125% due August 15, 2021 for the Teva IV BV 2021 Notes

 

2

Benchmark Treasury Yield:   

0.395% for the 2014 Notes

0.918% for the 2016 Notes

1.994% for the Teva BV 2021 Notes

1.994% for the Teva IV 2021 Notes

Optional Redemption:   

The Floating Rate Notes will not be subject to optional redemption at their applicable issuer’s option.

T + 20 basis points for the 2014 Notes

T + 25 basis points for the 2016 Notes

T + 30 basis points for the Teva BV 2021 Notes

T + 30 basis points for the Teva IV BV 2021 Notes

Joint Book-Running Managers:   

Barclays Capital Inc.

BNP Paribas Securities Corp.

Citigroup Global Markets Inc.

Credit Suisse Securities (USA) LLC

Goldman, Sachs & Co.

HSBC Securities (USA) Inc.

J.P. Morgan Securities LLC

Morgan Stanley & Co. LLC

Teva and Teva BV, Teva LLC and Teva IV BV (together, the “issuers”) have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents Teva and the issuers have filed with the SEC for more complete information about Teva and the issuers and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Teva, the issuers, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll free at 1-888-603-5847, Citigroup Global Markets Inc. toll free at 1-877-858-5407, Goldman, Sachs & Co. toll free at 1-866-471-2526 and Morgan Stanley & Co. LLC toll free at 1-866-718-1649.

Any disclaimers or other notices that may appear below are not applicable to this communication and should be disregarded. Such disclaimers or other notices were automatically generated as a result of this communication being sent via Bloomberg or another email system.

 

3

GRAPHIC 2 g253424001.jpg GRAPHIC begin 644 g253424001.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`(`!J`P$1``(1`0,1`?_$`+8```("`@,````````` M``````@)!PH#!@`$"P$``00#`0$`````````````!0,$!P@"!@D``1````4# M`P(#!`0+"0$``````0(#!`41!@<`$@@A"3%!$U%A(A1Q,A464C,D-#4F-E<8 M.!F!8E-C5(87)S;.[:ZKWDR9><+S9+36(I`"GP20I2?<)'N\X-TG M::S@!`KW#\R4``*!@@(@U:>8_E@=1T-I]0)I5$*0.U*8F1CRFYO14CE+59TL MAP*$^^J0;3.R^.#VFB]F(1286ZXC8R.1 M5&1GX]F*I7"#A13H5&GAK.BKR5@X09B?LCHC3-SMB\_V^TNC.CG,UI* M!(NU%LTK5/UC+W(F3$W;3SOD[&=B9#=<_KD/+4!CH2.&<=%DC`F455?GDQ]4 M_P`T"16XB(>W3JFJ&JA2B`)V2_1!H,^U-G-VV9NOZ@^:4Q>$:NMA8")WHF7;D.HFDL#O<9/HPJ4_B):=+=N`FPRN/;;!SF[46?`.:G< M-S0T3.!D$DR6]$J"1#T1!0NY1U7:=-.M?$*#H4BMIPNZ?4!SZ[XF#+?+/K2G MV6R,$CT@6B5_5$+:VVOU? M0:SRW:O*LT#K]4&JQU06^HH4V_W*TSGC2`FTB13Q,,!)VG,WT.-;_+\PBG/BM5 M?S5/^G^-V_\`Q??#1>..+.ZSP_99+MO#6"L2S$'?E^R%\.'5].WSR1!^Y8QL M2V033B[XBDOEQ09`;;UH`>6AV)FJ3)TI`!-N)/;Q/*+5;<9!Y@]LLN>RS)LN MR\L((406JDS4I9NP]W^+ZX89VV>8N>N4CO/L#G6`QY`7)AJ[V=I+M+"BYIB@ M9YZ"H/?6^TK@N+U#IKD,4-H@'2N@M=1L(/T6CY2B==@=W];;FU=70:F8H6JB MD*P0EMQ%J'@U[[B^FV0G$U]P;D;?G%+C-=&9\D7'LNA2F:WW=TYAX(D<;7/@7#C*P\F1D*]"=M<7<=(* M1P.64VQ.A:JAHOEQ8!22>7Z(N!I+3>=9;M5E MNF0M%/G%-EZ&EX%*0E*T@W2`4!U@&%@H]O+N&'2*=3N4740WX(6LY4`"@80( M4#EEDQ4$A``!-M`1$*^.E"_1\O0(K^]LEO/F+[CU/J%YEM1$@*^L1*SD&R+P M8!/G3QAY/X(BL#W'G3EI.Y_MN1S_`&7"Q=MO(A2/+&3#HWS"+XOJ.W'Q`@V4 M*)A&H%.(!T'63+J"X5-6)[!\\0CNYM5N1IKX$O4>=*J:=M57ZRZVI7>&[9N( M2#>!;RE>(M-PP?D,4:I=OR$86GL.#)&NWR\="7'#WA1;.?RG'2?*J>K\*P\E MT*I^X;GZQ-R`#T6FWIA(/9QH.3NXCT$:(^&CE?,LI) M-EG7[/"*H^5XL(S+43["G"VO.JM)PD%,Q5+)NLOOATM[7=;]C6M<5WW1(H14 M':\))S\N]54%%%E'0C=5\Z=&'<&\"E2``)XG#X:#6F@[;"BY^4\8M1J#.Z+3 M^35FI:I3@HZ1EPJNE-M*G#>4BY/%0[+X3)VP;2N'/F6>0'<-R+%BSD,J7,]M M#$;!Z8ZBL'8,2Y,W<"U(IN*"``DDR`Q!`#BU$W4!T[<0XA:029%%D5;\ONGA MK;5^>;O9R:E3:\PJ118R2GPSP;?3@QA8"1.SNW,`,Y3-L;]#9GRJX[QEQX24 MO&6'$++!4?.M+&2`Y8Q&?5MUTX<21R"IZ`J*+D`Y1`O0P>W2S],4LI>!L*1Z M28.-:YS1WS&?TPVNJ^&O4M2O#->&;;*2+,>&\WX3T$0;G.PI3<,>49!H.W!N M1Q```-X_JO("&_Q`P=.NF]$E2JM/ZJA\Z3Z>43!N@ENHV\S*G67IH93.1MM6 MDB*1?3^]_+)ZGG]?\/Z??XZ)>'7Z?EPCB'XIC^)572]K[X]")(IA,F*Z:8"! M@%(2_$.X/;4/AH'AH$H(02EDD)E:+H[_`*EL)">[6X5+,C,7RNGU<(1MVD!V MYI[AU*A_W^IMVA0O47]=PA2@".C&8(3X5)D)^GV8I#Y9',.N\_#H<">^?X&1 M'C561.?>?3(/`Z_!,0H[KPQP(]*_%][HP@C7V[>GT:'Y6\C&J:9@3X>F)%\U MJE-Z`HU-+4RLYH@3382"P_8>BST0P'!):X1Q$;:43#CJRZB/0W6"8&$W3SW# M7Z1UA4.)-0H*G(DQ*VVA?5MMD2?;'PZD))-L^Z3,]?&-HO.0GXFUKH?6G%I3 MMQQL6]?P4*N=9-*4DFK4ZS5B=5L8BP`X6*!*%,`]=9-M,R3C`"92L`[+#&YY MLJOH,LJ*S)DM5&9$%00XJ29R/JV6B$Q)3/&>W<*V0PY`6-)0MRQ#FX7KU[/`*[9%FX;OI%PDDGZ:BE M/$1#1&@R]"C^\5*?"8Z?NB`MV=<;IZNE2 M2$X4\;"H]46GHK:G%1!?$Y6#`PF33*;ZC1`1^$>A1.7P\ZCH`ZT%/%4Y6\>/ M".E^5D-Y?3-,)'ARR@"7ZH/"%&=K?#V5,27SS??Y&L"X;+87WG5:Y;0?3Z"; M<;IA?4GA"2C2E.H/RR171`"M!ZZ)UG[NG2V25+!!$^,QS'`2BKOESTQJ#(:S M/:"NI4T[;V:U;S9$Q,.5*B%`D`3D9CZ8UWNXY=NBVW@F*7W"/71"H?G2(:]W"+>TQ6RGIWF_-52.H4`1EM9Z@-@_?EB="!_RE*'LH5>.%\HS%3H5B*?9*2.5O."V[FY>O\`7NCZ>GS/2B$):S)*Q_NBJ82TXD*([M.&>,WS ME=!"6/W,>65D6;:=G%[;&;I(MK6Y#6\60(SO%N5^2(8-V`/"(?-*?82$ MW=R>`YQLH=U+ED4QCD[9&<@WCN-M1O(-QO:(A8=?`/HUXY.RM(#CJIC\OWP= M&_\`NFA2W:;0K*GEF9/Q&4SS,Z>,H]UKEL`!_P#,K.1:=`'T+PZ?1^H0:Q&1 MT_\`$4?V/OC%CS&[OM$IK-#M(1T9CB^BG/1`6\SN3G*WE[;6,[;/P(SA81,> MY2@LC@Z"W[SF?M8T&BOLC/CM./*U%8P_6**E*ATKIQ2Y4$O$8U%(YIE]<0]N MYN)NEN30TV6KTDFFRYDN!"A68RLK[LJ!26D$2*+.6#(B+3^F?F MU4Z""+7<#>]"BN5ND1(ABD/8>XHG`M?,/>/CH?4Y4LN`IQ*;!)!PV"?;V1+[ M/F+W0RVKHM.LZ/0IE(0E2_&D2'=BV7AR+Q<51V![JO*]80*/;-S<)5-Q$]J5 MXJ45(`E$BWZBE]`@[O$*B.G/PE3;6,J5CY88\OS);FE0TVYM]"T\;6@>W[O;,,812PHH.ODW MAK=<'=&4(#LYC"BE^>'&G4!!U342'&U)(*5GC*9-@X3B&J'6VZ36Y:]Q-2Z7 M0M+;12E`J\6`A_OD2*6RHR!5*:;^=D'DGW4>5YDTZ=M+.)$5O2,V%=M>)5R% M$P);E$RV,IL2*(;@-N$:>6F/PT=^0G'9,'U>/3$X_P!Q.Y;:C5(TBA?B?7;) MK2DAM=@F/#V=1"3U0$#'D'RR9\ZY/FN7@AFXSR4QNA8)\=*V_=8$*#.,<,#2 MJ,X6U_7$AP4`PE%KH@YES:Z8($Y)`&*5QG,6?5$*'66Y5-O92[A_TT@UAH:D M%GQ7JR4@)M=P&T89VI$^%T$SF/G]RWSQB+)F&$.W)F>"5R59=RV22=73N_IOQ?YK[_'WZ)2/IBGW_`)?NU_(O<_[#5_S^F/_9 ` end GRAPHIC 3 g253424002.jpg GRAPHIC begin 644 g253424002.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`)0!D`P$1``(1`0,1`?_$`-T```("`@,!```````` M``````D*``@!!P(#!@0!``$%``,!`0````````````<`!08("0,$"@(!$``` M!`0#!0((!!`/```````!`@0%$0,&!P`3""$Q$A4)018B%%25U1<8&8$TU'5A M<:%"LB,S$RDM(5%A=A@;%"4E0FH<%RLL*SE,0V M5A@X"1G18H(C,X2T189'HG/3)$1T)5759E?_V@`,`P$``A$#$0`_`"V=8*C2 M7$UW6'H*8M,VRZRHRCZ9.XEEYQD17FLG1"*HLH1`)AI`3N+A'8,(8*UC%]7D M"\0`5A3.>PXJKZ?R&F] M==+:-PN.I5):E3(E!JU,SRB*4GC3"X/0D!M"8,N8)10Y?]J'A1[,25*T)E)` M:=Z)QBOS7O\`&`,+5>G&S?#RK:#@[D`F9CH112#K6C<):Z1U75'TNJ.PXV([ M[@QH[-0KM#L_-)'\KQ&NT(_FX>PX+::`D-P=<=R-'YK MB*V])0>*.6H MI1*21,5!*,*8D\Y%0G))-.``.(`(@6,-N$%X1GYT.%5X>-P-QK?9TPX(G&'M M&<5Z@U0&'``$SAJ@(@=[GN?W'L.;2+H(:=0MYKL6$KVXRZU]S+9J%Q9+.++( M6\\3M2XR!U/)SYTLY9R6))P%`1C(.!MT<26<6A/+H%&80Z0*PJKJ7N<\'@^C M'X6K%4IG MNW)UX`>#VK#=YLV0]N+Y9S M=4I,S()RH5@!<$ZPJ:(X%I*\`![WX6(R?H&LY2F,.H5T@4IC;:21_6@(A&"H M1A_'#$;"\(_FPD]1\P\7C#BAX?!&$=F")IQU+6W!6T59W>K.;.+JR7KQU0TN9TGJFD=BT^A MKUU_P!?V4_U:7[(NS%N!HVG M#+F::X!UM]1([=JFX'TH]V&G^@,$B9?(9#\CPMF3=@(_3RM$_+&^]$9C((0[ M,#=M-G@V(A'L_E#^;"W&3+V=3"B7_2AJDLUKWMHD,G;5CXVT_<],C(:7(5K9 M'$2:=P+()\6J9@"9(G&,,9L^40-XX(MEUTIM*UI!%#G@01((Y!]XP80,`A MB;UP;@_KQP,],NKH2_>R:N?QBMO\V38)$^^24+^1X!;,[9]^N#;#V47[Z#,3 M3ON,W[W,^P'`X#"VERG$'<'P,A/`/:^_:)A\'?\`W8L)^Z/U?W#>=C^=?\2_ M'6NKT[-.%PM:]X`N;5EZWCF%AWZA7\>^$AWK=Q?4!'>`,X1@,MMFPV*LT#N=2Z\*5U ME$NKF$YJJ)TOTVE M``?7?^B%SG8V)/B,-:1E+JDL57&H?JM:D;>6^NVZV7J";4M5NA*S9I;G-7$2 MM[`TS5+>!6AZ85>4N)X)OP@"@&\H[L%U&/0EMDH>(B$2KIN*%47.IQT@/@;' M"<7?6@O+VO[2V:LU.5I',C1$2IK28*"8"D3*)B.251,XP4#GNR@+7B'I*ZKQ MV^\5N%M_N%>_^IAACZX2C_;4]\G]FQZ^AI?#_P"F3+DQG_(-9C25H%OSIZO` MDN+<#5_5UY:=3L#PT3**>$E524%BM2TL.HF,*H6 M)`@F/5JG_.Q:Q7EJH22$-6M,U,CZ#6!O0N^E M5Z%AIA8F;N+#QJ(@52K6%)4*4U2@+GF3,XP9<#+=:A],6J;IHL=H;KTUJ2JN MXU!4]73:AG4TWEJBG*6I^=(4"](6]QIV953RU*V%_/(42II!+*)F&`H@(S`P M399-)3:@ZT(K#$3B#)B+QJF,;$(@:J!GE!PX1]1LN;S;J+W-E:726V$JM1%S M.SD-,"%%`FL(H(B`Z4A#HC$*IF26$#E,#BA6%P@(F9G"TURJ?O#;6A[H4K/! M0P5S3;743>(F(,R3+<$I)TQ)/`IC`14CG":5-)&)3D$!P+8R%4@8I2%6!RB9 MA`>]C[X>LVKUC;4RRVUE("ULH-6ETPA4UR8'@!R@(E,Z@#%%Y3!B,`@V@+(Z M++6V5O#=6_3=.>'VYUV'MU<71V<58RT#,V.:@%`LK.UI\M,20!R`)YTX)L\P M[`,!=F._'SR*CH-*7B`%A4B@``&$1`,(B/K,.;!7%V2L);2;WA0YEHBU4WB% M#G4.9Q$DU#5M$FF5Q7/!XF-6..(0"AK?SON,[[V?[`<-`86-2G$-N#X&0H_2 M^_:*_P"_XL)^Z/U?W#>=;^=?\2_'6,IT"H\PU%;Q`$E$!&&R.<[_`%88@UX= M!8;(\WK->3[.8!UFTPXM'"^V59DC`S;4=I#"9-,)DRYNFN/OM]1/XS<`=V[\ MV&F&"/,G]1H<:'!4\+9E78`/T\[1;L;[T1F,0W8'#::MG"5)VM3.*)BMM1(X+Z<=`@`F`6YZ32)H@&TQ2B&X1QWI7' M'EL>E&$?F&!_=#`(=\'L/;U;!P%YEW\TL5'@6K&PQ@3,/B+%ST%,N8J4AMP' M8V$AT8;U/;*ENKHVN/..@K*TU0.KM2[2N.?QN6UF<9R.KV>00^T9;)4`!/W` M'"NV;`Q,;;0)%-#.H4`,@J4`,(8'NS1W1"CO-3'88MY'R]*;W'6I,*<\D\2H MH@F=]8$ZXEB4BOQ)+9^XK10#'EA]3MP/PR-H@W7.CE38;?M4S8&\?!&$,?0< M8-UOD])!RN%D*?TP>&&WVB-VW?W_`/X?#BPC_P#1WO!VK^X;SJO'MJ?_`-E^ M.MZ?2[+U9YM7>R9E_#C@FO1&9TOH<= M6OZKJ&>KHRWQUXWL=/.=)5)K.ID#`\='7S\KW=]K>9?6`\LU2^;4GI7#/Z'9 M(3?X&-=7;4\NUW(+SVF7U@/+-4OFU)Z5PO0[)";_``,JNVKY=KN07GM,OK`> M6:I?-J3TKA>AV2$W^!E5VU?+M=R"\]JETC+U=^TA5_#XCP9D/K(8=E>ANCB:;0]&457\7N.H8-R8M]7:A%]"'G7:J] M76-&0NM<4-+7S_)=6[C6TR^L!V+-4OFU)Z5PT^AV2$W^!C)5VU?+M=R`Y[3+ MZP'EFJ7S:D]*X7H=DA-_@95=M7R[7<@O/:9?6`\LU2^;4GI7"]#LD)O\#*KM MJ^7:[D%Y[3+ZP$?CFJ6/S:D]*X7H=DA-_@95=M5_'M=R"\]J?4M+U7>T>^]S MEEU_::SWKO'R-MD=]\_@E\^YMXJZY6[@\8S-G'#B\*&'A7HCHTNFT/1;@JOX MKL3J-Y@C)RWP]J,1T&><]JM=73Z(@:U6=^=TE4[LE>M0]SZ6N#E]8#RS5-YM M2^E<,P=3<00F_P`#&ZKMJ^7:[D%Y[<32^K]`>)9JDAPC&+:DAPP\*/Y5W0PA MZFNI"$=N\#(2[:CA>>UU7V!>>PP*ZS:YY!=+K&D]GQ])_2;__V3\_ ` end